Aptamers Engineered Nanocarriers for Cancer Therapy

Häftad, Engelska, 2022

Del i serien Woodhead Publishing Series in Biomaterials

2 574 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt över 249 kr.

Beskrivning

Aptamers Engineered Nanocarriers for Cancer Therapy details the selection technologies, biological characteristics, and clinical uses of aptamer-based nano agents for cancer therapeutics. The book helps facilitate speedy solutions for some of the problems pertaining to the manufacture of nano-aptamers - such as toxicity, thermal stability, cost efficiency, tumor penetration and blood stability. Key chapters cover cell-SELEX technology for aptamer selection, mechanisms of multi-drug resistance of cancer, the relevance of aptamers as anticancer therapies, as well as the broad range of aptamer-functionalized nanostructures available.

This book provides exciting insights into this relatively new approach to cancer therapeutics, and will be of interest to materials scientists, biomedical engineers, molecular biologists, biochemists and clinical scientists, with a focus on cancer therapy.

Reviews the mechanisms behind multi-drug resistance (MDR) in cancer and how aptamer-mediated novel therapeutic agents and strategies can facilitate MDR reversal
Covers a range of aptamers engineered nanostructures, including PLGA nanoparticles, silica nanoparticles, quantum dots, nucleic acid aptamers, and more
Discusses the challenges associated with using aptamers as cancer therapeutics and how this translates into clinical use

Produktinformation

Utgivningsdatum:2022-09-28
Mått:152 x 229 x 29 mm
Vikt:1 000 g
Format:Häftad
Språk:Engelska
Serie:Woodhead Publishing Series in Biomaterials
Antal sidor:556
Förlag:Elsevier Science
ISBN:9780323858816

Utforska kategorier

Onkologi inom Medicin
Biokemisk teknik inom Naturvetenskap och teknik
Biomedicinsk teknik inom Medicin

Mer om författaren

Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. He has over 12 years of teaching and research experience, specializing in translational nanomedicine, polymeric biomaterials, targeted drug delivery, and nanoengineered drug delivery systems. He has authored more than 400 peer-reviewed publications in reputed international journals and edited over 30 international books. His research has received widespread recognition, with an h-index exceeding 100. He has secured several competitive research grants from national funding agencies and received prestigious honors, including the USERN Laureate Award and the SERB–Ramanujan Fellowship. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and translational pharmaceutical research. He actively contributes to academic mentoring, scientific research, and scholarly publishing.

Innehållsförteckning

1. Cell-SELEX technology for aptamer selection2. Biological characteristics of aptamers3. Mechanisms of multi-drug resistance of cancer4. Relevance of aptamers as targeting ligands for anticancer therapies5. Aptamers as smart ligands for nano-carriers cancer targeting6. Aptamer-functionalized liposomes for targeted cancer therapy7. Aptamer-functionalized micelles for targeted cancer therapy8. Aptamer-functionalized nanoparticles for targeted cancer therapy9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy12. Aptamer-functionalized dendrimers for targeted cancer therapy13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy14. Aptamer-functionalized quantum dots for targeted cancer therapy15. Cancer immunotherapy via nucleic acid aptamers16. Aptamer-based imaging and diagnostics for cancer cells17. Microdevice-based aptamer sensors18. Aptamer-based microfluidics for circulating tumor cells19. Aptamer-based theranostic approaches for treatment of cancer20. Challenges of aptamers as targeting ligands for anticancer therapies21. Clinical use and future perspective of aptamers